Synbiotics (prebiotics and probiotics) in the nutrition of critically ill patients

C. Anastasilakis, O. Ioannidis, M. Papaioannou, Dimitris Tatsis, Maria Chasampalioti, P. Christidis, S. Symeonidis, S. Bitsianis, E. Anestiadou, D. Botsios, S. Angelopoulos
{"title":"Synbiotics (prebiotics and probiotics) in the nutrition of critically ill patients","authors":"C. Anastasilakis, O. Ioannidis, M. Papaioannou, Dimitris Tatsis, Maria Chasampalioti, P. Christidis, S. Symeonidis, S. Bitsianis, E. Anestiadou, D. Botsios, S. Angelopoulos","doi":"10.59869/23003","DOIUrl":null,"url":null,"abstract":"Background: It is well known, nowadays, that intestinal microbiota is considered to be a synbiotic partner that maintains the host’s health. Probiotics are live microorganisms and prebiotics are selectively fermentable non-digestible oligosaccharides or food ingredients that when adequately present, provide health benefit for the host. The mechanisms in which these microorganisms are involved are gastrointestinal barrier function improvement, gut flora modification by antimicrobial peptides inducted by host cells, antimicrobial factors released by probiotics, epithelial adherence competition, and immunomodulation that advantages the host. Synbiotics are a synergic combination of probiotic bacteria and prebiotic ingredients that promote the growth of the former. Methods: In the present study, the existing evidence regarding the beneficial role of probiotics, prebiotics, and synbiotics in critically ill patients was evaluated. Results: The results were rather encouraging about the early use of pro/pre/synbiotics in daily care of critically ill patients but still controversial due to the lack of specific supportive evidence and strain specificity. Conclusions: Despite the positive effect of pro/pre/synbiotics supplementation, they cannot be widely applied in critical care clinical practice until well-designed prospective and randomized controlled trials are performed.","PeriodicalId":86455,"journal":{"name":"Hellenike cheirourgike. Acta chirurgica Hellenica","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hellenike cheirourgike. Acta chirurgica Hellenica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.59869/23003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: It is well known, nowadays, that intestinal microbiota is considered to be a synbiotic partner that maintains the host’s health. Probiotics are live microorganisms and prebiotics are selectively fermentable non-digestible oligosaccharides or food ingredients that when adequately present, provide health benefit for the host. The mechanisms in which these microorganisms are involved are gastrointestinal barrier function improvement, gut flora modification by antimicrobial peptides inducted by host cells, antimicrobial factors released by probiotics, epithelial adherence competition, and immunomodulation that advantages the host. Synbiotics are a synergic combination of probiotic bacteria and prebiotic ingredients that promote the growth of the former. Methods: In the present study, the existing evidence regarding the beneficial role of probiotics, prebiotics, and synbiotics in critically ill patients was evaluated. Results: The results were rather encouraging about the early use of pro/pre/synbiotics in daily care of critically ill patients but still controversial due to the lack of specific supportive evidence and strain specificity. Conclusions: Despite the positive effect of pro/pre/synbiotics supplementation, they cannot be widely applied in critical care clinical practice until well-designed prospective and randomized controlled trials are performed.
危重病人营养中的合成菌(益生元和益生菌)
背景:众所周知,如今,肠道微生物群被认为是维持宿主健康的合生元伴侣。益生菌是活微生物,益生元是可选择性发酵的不易消化的低聚糖或食物成分,当其充分存在时,可为宿主提供健康益处。这些微生物参与的机制包括胃肠道屏障功能的改善、宿主细胞诱导的抗菌肽对肠道菌群的修饰、益生菌释放的抗菌因子、上皮粘附竞争以及对宿主有利的免疫调节。益生菌是益生菌和益生元成分的协同组合,促进前者的生长。方法:在本研究中,评估了有关益生菌、益生元和合生元在危重患者中的有益作用的现有证据。结果:在危重患者的日常护理中早期使用益生菌/益生元/合生元的结果相当令人鼓舞,但由于缺乏具体的支持性证据和菌株特异性,这一结果仍存在争议。结论:尽管益生菌/益生元/合生元补充剂具有积极作用,但在进行精心设计的前瞻性和随机对照试验之前,它们无法在重症监护临床实践中广泛应用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信